Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-21-007025
Date:2021-01-31
Issuer: TRAVERE THERAPEUTICS, INC. (TVTX)
Original Submission Date:

Reporting Person:

DUBE ERIC M
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DR., SUITE 300 SAN DIEGO, CA 92130

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-01-31 A 15,000 a $0.00 160,079 direct
COMMON STOCK 2021-02-02 S 6,328 d $29.60 153,751 direct
COMMON STOCK 2021-02-02 S 2,406 d $30.75 151,345 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 on january 31, 2020, the reporting person was granted a performance restricted stock unit (prsu) grant covering 30,000 shares of the issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. on january 31, 2021, a portion of the prsus vested upon the 12 month anniversary of the date of grant, following the issuer's prior confirmation of the satisfaction of a performance criterion related to the full enrollment of the duplex study.
f2 represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. this sale is mandated by the issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the issuer. this sale does not represent a discretionary trade by the reporting person.
f3 the sales reported in this form 4 were made pursuant to a written plan meeting the requirements of rule 10b5-1(c) of the securities exchange act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

Elevate your investments